Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells $19,638.50 in Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Janet Jill Hopkins sold 2,534 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $7.75, for a total transaction of $19,638.50. Following the transaction, the insider now directly owns 269,794 shares in the company, valued at approximately $2,090,903.50. The trade was a 0.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Aura Biosciences Trading Down 0.3 %

Shares of AURA stock opened at $7.63 on Friday. The company’s fifty day moving average price is $8.01 and its 200-day moving average price is $8.74. The stock has a market cap of $381.12 million, a PE ratio of -4.41 and a beta of 0.29. Aura Biosciences, Inc. has a 12 month low of $6.63 and a 12 month high of $12.38.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on AURA. HC Wainwright reaffirmed a “buy” rating and set a $22.00 target price on shares of Aura Biosciences in a research note on Thursday, November 14th. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research report on Friday, January 31st. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $23.00.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. BNP Paribas Financial Markets purchased a new stake in Aura Biosciences in the fourth quarter worth about $50,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Aura Biosciences in the 4th quarter worth approximately $87,000. ProShare Advisors LLC bought a new stake in shares of Aura Biosciences in the 4th quarter worth approximately $127,000. Harvest Investment Services LLC purchased a new stake in shares of Aura Biosciences in the 4th quarter worth approximately $133,000. Finally, AlphaQuest LLC bought a new position in Aura Biosciences during the 4th quarter valued at approximately $136,000. 96.75% of the stock is owned by hedge funds and other institutional investors.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.